Australian (ASX) Stock Market Forum

4DX - 4DMedical Limited

closed at 78c, up 70 per cent
and holding ..
Screenshot_20231120-103734_CommSec.jpg

.
announcement out today ...US is the big market
.
Highlights
• 4DMedical receives U.S. FDA clearance for CT LVAS™
• FDA clearance expands patient accessibility to 4DMedical’s ventilation reports by leveraging readily available CT hardware in the U.S.
• Clearance for CT LVAS™ significantly de-risks the regulatory pathway for CT:VQ, 4DMedical’s ventilation-perfusion product
.

- CT LVAS™ clearance broadens the accessibility of functional lung imaging in the U.S.
- CT LVAS™ provides an almost identical report to 4DMedical’s proven, FDA-cleared, XV LVAS® product, but utilises widely available Computed Tomography imaging infrastructure (instead of X-ray equipment), providing clinicians and patients with greater access to XV Technology
®.
 
prospectus out, back trading in low to mid 80's.

Upfront consideration for acquisition to be funded by capital raising, raising A$35.0 million
• Issuing approximately 44.3 million shares at an Offer Price of A$0.79 representing a discount of -17.3% to the last close

Highlights
4DMedical has signed a binding agreement to acquire U.S.-based medical technology company Imbio
• Imbio is a recognised leader in lung and heart artificial intelligence -driven technology, with a focus on providing structural analysis that delivers visual qualitative and quantitative assessment of lung and heart anatomy
• The Acquisition expands 4DMedical’s product offering to clinicians by incorporating Imbio’s highly complementary suite of diagnostic products, including its four FDA-cleared products
• Imbio is forecast to deliver US$3.0 million in revenue in CY2023, US$6.3 million in CY2024, and to be cashflow positive in the first 12 months post integration
 
the slump is over ... ?? up 40 per cent to $0.63

27 September 2024
Highlights
• 4DMedical announces the signing of a comprehensive distribution agreement with Philips, establishing a transformative commercialisation pathway in the U.S.
• Philips will have exclusive distribution rights to the 4DMedical suite of products with U.S. government customers and non-exclusive rights with all other U.S. customers
• 5-year agreement will leverage Philips’ long established and significant existing commercial partnerships with both the VA and the Department of Defense
• An investor webinar will be held on Tuesday, 01 October
 
Top